Linsidomine Hydrochloride manufacturers and suppliers on PharmaCompass

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Sin-1, Mls000028691, (3-morpholino-1,2,3-oxadiazol-3-ium-5-yl)amide hydrochloride, Smr000058925, 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium chloride, 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride
Molecular Formula
C6H11ClN4O2
Molecular Weight
206.63  g/mol
InChI Key
NCGICGYLBXGBGN-UHFFFAOYSA-N

Linsidomine Hydrochloride
1 2D Structure

Linsidomine Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride
2.1.2 InChI
InChI=1S/C6H10N4O2.ClH/c7-6-5-10(8-12-6)9-1-3-11-4-2-9;/h5,7H,1-4H2;1H
2.1.3 InChI Key
NCGICGYLBXGBGN-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1COCCN1[N+]2=CC(=N)O[N-]2.Cl
2.2 Synonyms
2.2.1 MeSH Synonyms

1. 3-morpholino-sydnonimine

2. 3-morpholino-sydnonimine Monohydrochloride

3. 3-morpholinosydnonimine N-ethylcarbamide

4. 3-morpholinosydonimine

5. 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium

6. Corvasal

7. Cv 664

8. Cv-664

9. Linsidomine

10. N-morpholino Sydnonimine

11. Sin-1 Morpholine

2.2.2 Depositor-Supplied Synonyms

1. Sin-1

2. Mls000028691

3. (3-morpholino-1,2,3-oxadiazol-3-ium-5-yl)amide Hydrochloride

4. Smr000058925

5. 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium Chloride

6. 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride

7. 3-morpholino-sydnonimine Hydrochloride

8. Molsidomine Impurity A

9. Opera_id_1704

10. 3-morpholinosydnonimine Hcl

11. Mls000860006

12. Schembl960238

13. Chembl538104

14. 3-(4-morpholinyl)sydnonimine Hcl

15. 3-morpholinosydnoimine Hydrochloride

16. 3-morpholino-sydnoniminehydrochloride

17. Tox21_500247

18. Tox21_500854

19. 3-morpholinosydnonimine Hydro-chloride

20. Akos022181148

21. Akos025213271

22. Ccg-221551

23. Ccg-222158

24. Lp00247

25. Lp00854

26. Ncgc00094181-01

27. Ncgc00260932-01

28. Ncgc00261539-01

29. Smr000326865

30. Mls-0003225.p022

31. Eu-0100854

32. Ft-0616203

33. M-184

34. J-009828

35. J-019356

36. (3-morpholino-1,2,3-oxadiazol-3-ium-5-yl)amidehydrochloride

37. 5-imino-3-morpholino-5h-1,2,3-oxadiazol-3-ium-2-ide Hydrochloride

38. 3-(morpholin-4-yl)sydnonimine Hydrochloride (linsidomine Hydrochloride)

39. 3-morpholinosydnonimine Hydrochloride, (consistent With Structure, Nmr)

40. 1,2,3-oxadiazolium, 5-amino-3-(4-morpholinyl)-, Inner Salt, Hydrochloride (1:1)

2.3 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 206.63 g/mol
Molecular Formula C6H11ClN4O2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count1
Exact Mass206.0570533 g/mol
Monoisotopic Mass206.0570533 g/mol
Topological Polar Surface Area49.6 Ų
Heavy Atom Count13
Formal Charge0
Complexity222
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antihypertensive Agents

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)


Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)


Nitric Oxide Donors

A diverse group of agents, with unique chemical structures and biochemical requirements, which generate NITRIC OXIDE. These compounds have been used in the treatment of cardiovascular diseases and the management of acute myocardial infarction, acute and chronic congestive heart failure, and surgical control of blood pressure. (Adv Pharmacol 1995;34:361-81) (See all compounds classified as Nitric Oxide Donors.)


Platelet Aggregation Inhibitors

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)


Vasodilator Agents

Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty